The Therapeutic Effectiveness of the Coadministration of Weekly Risedronate and Proton Pump Inhibitor in Osteoporosis Treatment

• Published in: Journal of Osteoporosis 2014-01, Vol.2014 (2014), p.70-74
• Main Authors: Yamashita, K., Yoshioka, Taro, Itoh, Soichiro, Tanaka, Mizue
• Format: Article
• Language: English
• Subjects: Age; Bioavailability; Bisphosphonates; Clinical Study; Constipation; Creatinine; Drug dosages; Drug therapy; Fractures; Leukopenia; Menopause; Metabolism; Nonsteroidal anti-inflammatory drugs; Osteoporosis; Pain; Physical fitness; Proton pump inhibitors; Risedronate; Sodium; Standard deviation
• ISSN: 2042-0064; 2090-8059; 2042-0064
• DOI: 10.1155/2014/607145

This trial was conducted to investigate the long-term effects of proton pump inhibitor (PPI) coadministration on the efficacy of weekly risedronate treatment for osteoporosis. Ninety-six women over 50 years old with low bone mineral density (BMD) participated in this trial. Subjects were randomly divided into 2 groups: a 17.5 mg dose of sodium risedronate was administered weekly, with or without a daily 10 mg dose of sodium rabeprazole (n=49 and 47 in the BP + PPI and BP groups, resp.). The following biomarkers were measured at the baseline and every 3 months: bone-specific alkaline phosphatase, N-terminal telopeptide of type I collagen corrected for creatinine, parathyroid hormone, BMD of the lumbar spine, and physical parameters evaluated according to the SF-36v2 Health Survey. Statistical comparisons of these parameters were performed after 6, 12, 18, and 24 months. The Δ values of improvement in physical functioning after 12 months and bodily pain after 6 and 12 months in the BP + PPI group were significantly larger than those in the BP group. These results suggest that PPI does not adversely affect bone metabolism. Alternatively, approved bone formation by concomitant PPI treatment may have had favorable effects on the improvement of bodily pain and physical functions.